BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C‐MYC/PLCG1/Perk Axis

BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C‐MYC/PLCG1/Perk Axis

Abstract Erlotinib, an EGFR tyrosine kinase inhibitor, is used for treating patients with cancer exhibiting EGFR overexpression or mutation. However, the response rate of erlotinib is low among patients with gastric cancer (GC). The findings of this study illustrated that the overexpression of bromo...

Full description

Bibliographic Details
Main Authors: Fangyuan Li, Junxian Yu, Tao Pan, Haoran Feng, Jianfang Li, Beiqin Yu, Zhiyuan Fan, Qingqing Sang, Mengdi Chen, Mingde Zang, Junyi Hou, Xiongyan Wu, Yingyan Yu, Yuan‐Yuan Li, Chao Yan, Zhenggang Zhu, Liping Su, Bingya Liu
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:Advanced Science
Subjects:
AU‐1
BPTF
EGFR‐TKI
erlotinib
gastric cancer
targeted therapy
Online Access:https://doi.org/10.1002/advs.202303091

Internet

https://doi.org/10.1002/advs.202303091

Similar Items